menu
    • menu
    [{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zelicapavir","moa":"N-protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zelicapavir","moa":"N-protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zelicapavir","moa":"N-protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zelicapavir","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Zelicapavir

    Menu

    Zelicapavir

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Enanta Pharmaceuticals

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Enanta Pharmaceuticals

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zelicapavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Enanta Reports Positive Phase 2 Results for Zelicapavir in Respiratory Syncytial Virus

                            Details : EDP-938 (zelicapavir) is a RSV N-protein inhibitor, small molecule drug candidate. It is being evaluated for the treatment of respiratory syncytial virus infection.

                            Product Name : EDP-938

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 09, 2024

                            Lead Product(s) : Zelicapavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Enanta Pharmaceuticals

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Enanta Pharmaceuticals

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zelicapavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Outlook for 2022 at the...

                            Details : Completes enrollment for RSVP, a phase 2 study of EDP-938 in community-acquired respiratory syncytial virus infection in an adult population; plans to report topline data in the second quarter of 2022.

                            Product Name : EDP-938

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 01, 2022

                            Lead Product(s) : Zelicapavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Enanta Pharmaceuticals

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Enanta Pharmaceuticals

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zelicapavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Co...

                            Details : In this low-risk patient population which had mild, self-resolving upper respiratory tract infection, EDP-938 did not meet the primary endpoint of reduction in total symptom score compared to placebo, or the secondary antiviral endpoints.

                            Product Name : EDP-938

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 18, 2022

                            Lead Product(s) : Zelicapavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Enanta Pharmaceuticals

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Enanta Pharmaceuticals

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zelicapavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Enanta Pharmaceuticals Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syn...

                            Details : EDP-938 is a nanomolar inhibitor of both RSV-A and RSV-B activity, in treatment of adults with acute respiratory syncytial virus (RSV) infection who are at high risk of complications.

                            Product Name : EDP-938

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 10, 2022

                            Lead Product(s) : Zelicapavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth